Premium
Evaluation of immunomodulatory effect of recombinant human granulocyte‐macrophage colony‐stimulating factor on polymorphonuclear cell from dogs with cancer in vitro
Author(s) -
Zhang Y.,
AxiakBechtel S.,
Friedman Cowan C.,
Amorim J.,
Tsuruta K.,
DeClue A. E.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12236
Subject(s) - granulocyte macrophage colony stimulating factor , respiratory burst , cancer , immunology , granulocyte , medicine , cytokine , phagocytosis , in vitro , immune system , cancer cell , colony stimulating factor , macrophage , immunotherapy , cancer immunotherapy , tumor necrosis factor alpha , cancer research , biology , biochemistry , microbiology and biotechnology , stem cell , haematopoiesis
The objective of this in vitro study was to evaluate the immunomodulatory effects of recombinant human granulocyte‐macrophage colony‐stimulating factor ( rhGM‐CSF ) on polymorphonuclear cell ( PMN ) function in dogs with cancer. PMNs were harvested from dogs with naturally developing cancer as a pre‐clinical model to evaluate the immunomodulatory effects of rhGM‐CSF on PMN phagocytic and cytotoxic functions, cytokine production and receptor expression. Some aspects of cancer‐related PMN dysfunction in dogs with cancer were restored following incubation with rhGM‐CSF including PMN phagocytosis, respiratory burst and LPS ‐induced TNF ‐α production. In addition, rhGM‐CSF increased surface HLA‐DR expression on the PMNs of dogs with cancer. These data suggests that dysfunction of innate immune response in dogs with cancer may be improved by rhGM‐CSF . The results of this study provided a pathophysiologic rationale for the initiation of clinical trials to continue evaluating rhGM‐CSF as an immunomodulatory therapy in dogs with cancer.